Chronic Type B Viral Hepatitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic type b viral hepatitis. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
2
Active US patents
72/100
Avg vulnerability
—
Annual revenue covered

Originators in Chronic Type B Viral Hepatitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

GSK 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic type b viral hepatitis. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
29

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Epivir
LAMIVUDINE
 GSK 2 72 — 2029-03-11

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7754731 Epivir method of use 75 2029-03-11
7754731 Epivir other 68 2029-09-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7754731 Epivir other 68 2029-09-11
7754731 Epivir method of use 75 2029-03-11

Related